[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Tranylcypromine.]
[B01AD01, streptokinase, Tranylcypromine may increase the orthostatic hypotensive activities of Streptokinase.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Tranylcypromine.]
[J01EC02, sulfadiazine, Tranylcypromine may increase the hypoglycemic activities of Sulfadiazine.]
[J01EC01, sulfamethoxazole, The metabolism of Sulfamethoxazole can be decreased when combined with Tranylcypromine.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, Tranylcypromine may increase the hypoglycemic activities of Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Tranylcypromine.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sulthiame.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Tranylcypromine.]
[A10BC01, glymidine, Tranylcypromine may increase the hypoglycemic activities of Glymidine.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Tranylcypromine.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Tranylcypromine.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Tranylcypromine.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Tranylcypromine.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Tranylcypromine.]
[N04BC07, apomorphine, Tranylcypromine may increase the orthostatic hypotensive activities of Apomorphine.]
[L04AX02, thalidomide, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Tranylcypromine.]
[R06AD03, thiethylperazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Thiethylperazine.]
[N05CA19, thiopental, The metabolism of Thiopental can be decreased when combined with Tranylcypromine.]
[N05AB08, thioproperazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Thioridazine can be decreased when combined with Tranylcypromine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Tranylcypromine.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Tranylcypromine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Tilidine is combined with Tranylcypromine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Tranylcypromine.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Tranylcypromine.]
[M02AX02, tolazoline, Tranylcypromine may increase the hypotensive activities of Tolazoline.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Tranylcypromine.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Tranylcypromine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome and seizure can be increased when Tranylcypromine is combined with Tramadol.]
[C01DX11, trapidil, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Trapidil.]
[N06AX05, trazodone, Tranylcypromine may increase the serotonergic activities of Trazodone.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Tranylcypromine.]
[C03DB02, triamterene, Tranylcypromine may increase the orthostatic hypotensive activities of Triamterene.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triazolam.]
[C03AA06, trichlormethiazide, Tranylcypromine may increase the hypotensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Triflupromazine.]
[N04AA01, trihexyphenidyl, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Tranylcypromine.]
[C02BA01, trimethaphan, Tranylcypromine may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Tranylcypromine.]
[N06AA06, trimipramine, Tranylcypromine may increase the serotonergic activities of Trimipramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Tranylcypromine.]
[A03BB01, butylscopolamine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Tranylcypromine.]
[N06AX02, tryptophan, The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Tranylcypromine.]
[C09CA09, azilsartan medoxomil, Tranylcypromine may increase the hypotensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tubocurarine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Tranylcypromine.]
[A10BH05, linagliptin, Tranylcypromine may increase the hypoglycemic activities of Linagliptin.]
[J05AG05, rilpivirine, The metabolism of Rilpivirine can be decreased when combined with Tranylcypromine.]
[B01AD04, urokinase, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Urokinase.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ezogabine.]
[B01AF01, rivaroxaban, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ticagrelor.]
[C08DA01, verapamil, Tranylcypromine may increase the orthostatic hypotensive activities of Verapamil.]
[N06AX09, viloxazine, The risk or severity of hypertension can be increased when Viloxazine is combined with Tranylcypromine.]
[C04AX07, vincamine, Tranylcypromine may increase the hypotensive activities of Vincamine.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Tranylcypromine.]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Tranylcypromine.]
[N01AX15, xenon, The risk or severity of adverse effects can be increased when Xenon is combined with Tranylcypromine.]
[C03BA10, xipamide, Tranylcypromine may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Tranylcypromine.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be decreased when combined with Tranylcypromine.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levetiracetam.]
[B01AE01, desirudin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be decreased when combined with Tranylcypromine.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Tranylcypromine.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Tranylcypromine.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Tranylcypromine.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Tranylcypromine.]
[J02AC03, voriconazole, The metabolism of Voriconazole can be decreased when combined with Tranylcypromine.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Atracurium.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Atropine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Tranylcypromine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Tranylcypromine.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Tranylcypromine.]
[M03BX01, baclofen, The risk or severity of hypotension can be increased when Baclofen is combined with Tranylcypromine.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Tranylcypromine.]
[G04BD12, mirabegron, The metabolism of Mirabegron can be decreased when combined with Tranylcypromine.]
[L02BB04, enzalutamide, The serum concentration of Enzalutamide can be increased when it is combined with Tranylcypromine.]
[B01AX01, defibrotide, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Defibrotide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Octopamine.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Tranylcypromine.]
[S01GA07, brimonidine, The metabolism of Brimonidine can be decreased when combined with Tranylcypromine.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rasagiline.]
[C08CA13, lercanidipine, Tranylcypromine may increase the hypotensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mosapride.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Tranylcypromine.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Tranylcypromine.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Tranylcypromine.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Diethyl ether is combined with Tranylcypromine.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Tranylcypromine.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Tranylcypromine.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Tranylcypromine.]
[B01AF02, apixaban, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Apixaban.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Tranylcypromine.]
[C03AA01, bendroflumethiazide, Tranylcypromine may increase the hypotensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Tranylcypromine.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benperidol.]
[A10BK02, canagliflozin, Tranylcypromine may increase the orthostatic hypotensive activities of Canagliflozin.]
[A06AX06, tegaserod, The metabolism of Tegaserod can be decreased when combined with Tranylcypromine.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Tranylcypromine is combined with Insulin detemir.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Tranylcypromine.]
[A10BX05, pramlintide, Tranylcypromine may increase the hypoglycemic activities of Pramlintide.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Tranylcypromine.]
[N02CC02, naratriptan, The metabolism of Naratriptan can be decreased when combined with Tranylcypromine.]
[N04AC01, benztropine, The metabolism of Benzatropine can be decreased when combined with Tranylcypromine.]
[L01EC02, dabrafenib, The metabolism of Dabrafenib can be decreased when combined with Tranylcypromine.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Tranylcypromine.]
[N06AX28, levomilnacipran, Tranylcypromine may increase the serotonergic activities of Levomilnacipran.]
[C08EA02, bepridil, The metabolism of Bepridil can be decreased when combined with Tranylcypromine.]
[C02KX05, riociguat, Tranylcypromine may increase the hypotensive activities of Riociguat.]
[A10BJ03, lixisenatide, Tranylcypromine may increase the hypoglycemic activities of Lixisenatide.]
[C02KX04, macitentan, Tranylcypromine may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Tranylcypromine.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Tranylcypromine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Eslicarbazepine.]
[S01EA03, apraclonidine, Tranylcypromine may increase the alpha-adrenergic activities of Apraclonidine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Tranylcypromine.]
[C01CA27, droxidopa, Tranylcypromine may increase the hypertensive activities of Droxidopa.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be decreased when combined with Tranylcypromine.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Apremilast can be decreased when combined with Tranylcypromine.]
[N07CA01, betahistine, The metabolism of Betahistine can be decreased when combined with Tranylcypromine.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Tranylcypromine.]
[B01AE03, argatroban, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Argatroban.]
[C02CC01, bethanidine, Tranylcypromine may increase the hypotensive activities of Bethanidine.]
[C10AB02, bezafibrate, Tranylcypromine may increase the hepatotoxic activities of Bezafibrate.]
[A10BJ04, albiglutide, Tranylcypromine may increase the hypoglycemic activities of Albiglutide.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Vorapaxar.]
[A03BA03, hyoscyamine, Tranylcypromine may increase the anticholinergic activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Tranylcypromine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alfaxalone.]
[A10BK03, empagliflozin, Tranylcypromine may increase the orthostatic hypotensive activities of Empagliflozin.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Tranylcypromine.]
[D11AA01, glycopyrronium, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Tranylcypromine.]
[N05AA04, acepromazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Acepromazine.]
[A10BJ05, dulaglutide, Tranylcypromine may increase the hypoglycemic activities of Dulaglutide.]
[N04AA02, biperiden, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Tranylcypromine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Tranylcypromine.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Tranylcypromine.]
[B01AF03, edoxaban, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Edoxaban.]
[N06AX11, mirtazapine, Tranylcypromine may increase the serotonergic activities of Mirtazapine.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Tranylcypromine.]
[A03AA09, difemerine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tioclomarol.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Tranylcypromine.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Eluxadoline.]
[B01AC25, cangrelor, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Cangrelor.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Tranylcypromine.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Tranylcypromine.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Tranylcypromine.]
[A10BF01, acarbose, Tranylcypromine may increase the hypoglycemic activities of Acarbose.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Tranylcypromine is combined with Insulin degludec.]
[N05AB07, acetophenazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Tranylcypromine.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Tranylcypromine.]
[B01AC27, selexipag, Tranylcypromine may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Tranylcypromine.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Tranylcypromine.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Tranylcypromine.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromazepam.]
[N04BC01, bromocriptine, Tranylcypromine may increase the hypertensive activities of Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tranylcypromine.]
[N06AA19, amineptin, Tranylcypromine may increase the serotonergic activities of Amineptine.]
[C08CA01, amlodipine, Tranylcypromine may increase the hypotensive activities of Amlodipine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aniracetam.]
[C03CA02, bumetanide, Tranylcypromine may increase the orthostatic hypotensive activities of Bumetanide.]
[N01BB01, bupivacaine, The metabolism of Bupivacaine can be decreased when combined with Tranylcypromine.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Tranylcypromine.]
[N07BC01, buprenorphine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Buspirone.]
[L01XX27, arsenic trioxide, Tranylcypromine may increase the orthostatic hypotensive activities of Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Tranylcypromine.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Tranylcypromine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tranylcypromine.]
[S01GX07, azelastine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Tranylcypromine.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Bambuterol.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Beclamide.]
[C09AA07, benazepril, Tranylcypromine may increase the hypotensive activities of Benazepril.]
[A10BX06, benfluorex, Tranylcypromine may increase the hypoglycemic activities of Benfluorex.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxybuprocaine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Linezolid.]
[J05AE09, tipranavir, The metabolism of Tipranavir can be decreased when combined with Tranylcypromine.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Tranylcypromine.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Safinamide.]
[B01AF04, betrixaban, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Betrixaban.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Tranylcypromine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Tranylcypromine.]
[C07AB07, bisoprolol, Tranylcypromine may increase the hypotensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Bitolterol.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Tranylcypromine.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Tranylcypromine.]
[N04AA11, bornaprine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[C01DX19, nesiritide, Tranylcypromine may increase the orthostatic hypotensive activities of Nesiritide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brotizolam.]
[C04AX20, buflomedil, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Tranylcypromine.]
[N06AA15, butriptyline, Tranylcypromine may increase the serotonergic activities of Butriptyline.]
[A10BJ06, semaglutide, Tranylcypromine may increase the hypoglycemic activities of Semaglutide.]
[A10BK04, ertugliflozin, Tranylcypromine may increase the hypoglycemic activities of Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vinylbital.]
[C09AA01, captopril, Tranylcypromine may increase the hypotensive activities of Captopril.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Tranylcypromine.]
[A03AA03, camylofine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tranylcypromine.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Tranylcypromine.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Tranylcypromine.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Tranylcypromine.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Tranylcypromine.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Tranylcypromine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Tranylcypromine.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Tranylcypromine.]
[N03AX17, stiripentol, The metabolism of Tranylcypromine can be decreased when combined with Stiripentol.]
[J01AA13, eravacycline, The metabolism of Eravacycline can be decreased when combined with Tranylcypromine.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Tranylcypromine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Tranylcypromine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carbromal.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Tranylcypromine.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Tranylcypromine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Tranylcypromine.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Tranylcypromine.]
[L01EX13, gilteritinib, The therapeutic efficacy of Tranylcypromine can be decreased when used in combination with Gilteritinib.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Tranylcypromine is combined with Amifampridine.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Tranylcypromine.]
[C09AA08, cilazapril, Tranylcypromine may increase the hypotensive activities of Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Caplacizumab.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Tranylcypromine.]
[A03FA08, cinitapride, The metabolism of Cinitapride can be decreased when combined with Tranylcypromine.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Tranylcypromine.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Tranylcypromine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Tranylcypromine.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Tranylcypromine.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Tranylcypromine.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Tranylcypromine.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cloxazolam.]
[C09CA06, candesartan, Tranylcypromine may increase the hypotensive activities of Candesartan.]
[N05AA06, cyamemazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Cyamemazine.]
[C03BX03, cicletanine, Tranylcypromine may increase the hypotensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the serotonergic activities of Tranylcypromine.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Tranylcypromine.]
[N07XX11, pitolisant, The metabolism of Pitolisant can be decreased when combined with Tranylcypromine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Tranylcypromine.]
[C03AA09, cyclothiazide, Tranylcypromine may increase the hypotensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Yohimbine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Tranylcypromine is combined with Insulin pork.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Tranylcypromine.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Tranylcypromine.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Tranylcypromine.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be decreased when combined with Tranylcypromine.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tranylcypromine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Tranylcypromine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Tranylcypromine.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Tranylcypromine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lumateperone.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Tranylcypromine.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Dutasteride.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Tranylcypromine.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tranylcypromine.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Tranylcypromine.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Tranylcypromine.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be decreased when combined with Tranylcypromine.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Tranylcypromine.]
[C01BD07, dronedarone, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tranylcypromine.]
[C02AA06, methoserpidine, Tranylcypromine may increase the hypotensive activities of Methoserpidine.]
[A03AA08, dihexyverine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Opicapone is combined with Tranylcypromine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Dopexamine.]
[G04BD09, trospium, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Selpercatinib.]
[B01AE02, lepirudin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Tranylcypromine.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Tranylcypromine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Tranylcypromine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Remimazolam.]
[N07XX04, sodium oxybate, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Tranylcypromine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Tranylcypromine.]
[C03AA04, chlorothiazide, Tranylcypromine may increase the hypotensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Tranylcypromine.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be decreased when combined with Tranylcypromine.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Tranylcypromine.]
[N05AF03, chlorprothixene, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Tranylcypromine may increase the hypotensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Tranylcypromine.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Tranylcypromine.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Etofenamate.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Tranylcypromine.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Naxitamab.]
[C01DX22, vericiguat, Tranylcypromine may increase the orthostatic hypotensive activities of Vericiguat.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Fenbufen.]
[C01CA19, fenoldopam, Tranylcypromine may increase the hypotensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Finasteride.]
[R03CC15, formoterol, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Tranylcypromine is combined with Insulin human.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trichloroethylene is combined with Tranylcypromine.]
[H04AA02, dasiglucagon, Tranylcypromine may increase the hypotensive activities of Dasiglucagon.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gabapentin.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Tranylcypromine.]
[N06AB04, citalopram, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Citalopram.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Tranylcypromine.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Tranylcypromine.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Tranylcypromine.]
[R06AA04, clemastine, Tranylcypromine may increase the anticholinergic activities of Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Tranylcypromine.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Tranylcypromine.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Tranylcypromine.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Tranylcypromine.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Tranylcypromine.]
[B01AD11, tenecteplase, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tenecteplase.]
[N01BB10, levobupivacaine, Tranylcypromine may increase the orthostatic hypotensive activities of Levobupivacaine.]
[N06AA04, clomipramine, Tranylcypromine may increase the serotonergic activities of Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Tranylcypromine.]
[C01EB24, mavacamten, The metabolism of Mavacamten can be decreased when combined with Tranylcypromine.]
[A10BX16, tirzepatide, Tranylcypromine may increase the hypoglycemic activities of Tirzepatide.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clotiazepam.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Tranylcypromine.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Granisetron.]
[N05AH02, clozapine, The metabolism of Clozapine can be decreased when combined with Tranylcypromine.]
[A10BX01, guar gum, Tranylcypromine may increase the hypoglycemic activities of Guar gum.]
[A10BK06, sotagliflozin, Tranylcypromine may increase the hypoglycemic activities of Sotagliflozin.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Halazepam.]
[S02DA02, cocaine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Tranylcypromine may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Tranylcypromine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hexafluronium.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Tranylcypromine.]
[A03AB10, hexocyclium, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Tranylcypromine.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Tranylcypromine.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Tranylcypromine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Imidazole salicylate.]
[H01AC03, mecasermin, Tranylcypromine may increase the hypoglycemic activities of Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Tranylcypromine is combined with Insulin glargine.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Tranylcypromine.]
[B01AC10, indobufen, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desloratadine.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Tranylcypromine.]
[A03AX10, isometheptene, Tranylcypromine may increase the sympathomimetic activities of Isometheptene.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Tranylcypromine.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Tranylcypromine.]
[B01AB12, bemiparin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Bemiparin.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Kebuzone.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Tranylcypromine.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Tranylcypromine.]
[C08CA09, lacidipine, Tranylcypromine may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Loxoprofen.]
[C09AA03, lisinopril, Tranylcypromine may increase the hypotensive activities of Lisinopril.]
[C08CA11, manidipine, Tranylcypromine may increase the hypotensive activities of Manidipine.]
[A03AA04, mebeverine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Mefenorex.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Tranylcypromine.]
[R06AD07, mequitazine, Tranylcypromine may increase the anticholinergic activities of Mequitazine.]
[N04AA03, methixene, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, Tranylcypromine may increase the hypertensive activities of Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclobarbital.]
[C03DA04, eplerenone, Tranylcypromine may increase the hypotensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Melperone.]
[C03AA07, cyclopenthiazide, Tranylcypromine may increase the hypotensive activities of Cyclopenthiazide.]
[A10BF02, miglitol, Tranylcypromine may increase the hypoglycemic activities of Miglitol.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.]
[N06AX07, minaprine, The metabolism of Minaprine can be decreased when combined with Tranylcypromine.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Tranylcypromine.]
[N06AG02, moclobemide, The metabolism of Moclobemide can be decreased when combined with Tranylcypromine.]
[R06AX02, cyproheptadine, Tranylcypromine may increase the anticholinergic activities of Cyproheptadine.]
[C09AA13, moexipril, Tranylcypromine may increase the hypotensive activities of Moexipril.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Tranylcypromine.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Morniflumate.]
[C03XA02, conivaptan, Tranylcypromine may increase the orthostatic hypotensive activities of Conivaptan.]
[C02AC05, moxonidine, Tranylcypromine may increase the hypotensive activities of Moxonidine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Tranylcypromine.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Tranylcypromine.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Tranylcypromine.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Deanol.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Tranylcypromine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Tranylcypromine.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nordazepam.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Tranylcypromine.]
[N06AX06, nefazodone, Tranylcypromine may increase the serotonergic activities of Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Tranylcypromine.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Tranylcypromine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiagabine.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tranylcypromine.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Normethadone is combined with Tranylcypromine.]
[B01AX05, fondaparinux, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Tranylcypromine.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Olsalazine.]
[N06AA01, desipramine, Tranylcypromine may increase the serotonergic activities of Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Tranylcypromine.]
[C09XA02, aliskiren, Tranylcypromine may increase the hypotensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxcarbazepine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxiracetam.]
[N04AA08, dexetimide, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Tranylcypromine.]
[A03AA01, oxyphencyclimine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Tranylcypromine.]
[N06BA02, dextroamphetamine, Tranylcypromine may increase the hypertensive activities of Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Tranylcypromine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Tranylcypromine.]
[N06AB05, paroxetine, Tranylcypromine may increase the serotonergic activities of Paroxetine.]
[B01AC04, clopidogrel, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Tranylcypromine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenacemide.]
[V03AH01, diazoxide, Tranylcypromine may increase the hypotensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phensuximide.]
[N06AA08, dibenzepin, Tranylcypromine may increase the serotonergic activities of Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Tranylcypromine.]
[R05DA08, pholcodine, Pholcodine may increase the serotonergic activities of Tranylcypromine.]
[S01EC02, dichlorphenamide, Tranylcypromine may increase the orthostatic hypotensive activities of Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Tranylcypromine.]
[A03AA07, dicyclomine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, Tranylcypromine may increase the hypotensive activities of Pinacidil.]
[A10BG03, pioglitazone, Tranylcypromine may increase the hypoglycemic activities of Pioglitazone.]
[N05AD05, pipamperone, Tranylcypromine may increase the orthostatic hypotensive activities of Pipamperone.]
[A03AB14, pipenzolate, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Tranylcypromine.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Pirbuterol.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diethylpropion.]
[C08CA03, isradipine, Tranylcypromine may increase the hypotensive activities of Isradipine.]
[A03AB11, poldine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Diflunisal.]
[C02DB01, dihydralazine, Tranylcypromine may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Tranylcypromine.]
[N02AA03, hydromorphone, Tranylcypromine may increase the serotonergic activities of Hydromorphone.]
[J05AE08, atazanavir, The metabolism of Atazanavir can be decreased when combined with Tranylcypromine.]
[B01AC21, treprostinil, Tranylcypromine may increase the hypotensive activities of Treprostinil.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Tranylcypromine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pridinol.]
[R06AB03, dimethindene, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Procaterol.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Progabide.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quazepam.]
[C09AA06, quinapril, Tranylcypromine may increase the hypotensive activities of Quinapril.]
[B01AC07, dipyridamole, Tranylcypromine may increase the orthostatic hypotensive activities of Dipyridamole.]
[N06BA11, dexmethylphenidate, Tranylcypromine may increase the hypertensive activities of Dexmethylphenidate.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, Tranylcypromine may increase the serotonergic activities of Quinupramine.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Tranylcypromine.]
[C09AA05, ramipril, Tranylcypromine may increase the hypotensive activities of Ramipril.]
[N05AL04, remoxipride, The metabolism of Remoxipride can be decreased when combined with Tranylcypromine.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Reproterol.]
[C01BA03, disopyramide, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Tranylcypromine.]
[N05AX08, risperidone, Tranylcypromine may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levocetirizine.]
[N01BB09, ropivacaine, Tranylcypromine may increase the orthostatic hypotensive activities of Ropivacaine.]
[L01EX01, sunitinib, Tranylcypromine may increase the hypoglycemic activities of Sunitinib.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Tranylcypromine.]
[G04BE08, tadalafil, Tranylcypromine may increase the hypotensive activities of Tadalafil.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Tranylcypromine.]
[C02KX02, ambrisentan, Tranylcypromine may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be decreased when combined with Tranylcypromine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Salmeterol.]
[C01CA07, dobutamine, Tranylcypromine may increase the hypertensive activities of Dobutamine.]
[A03FA03, domperidone, The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Tranylcypromine is combined with Domperidone.]
[C01CA04, dopamine, The metabolism of Dopamine can be decreased when combined with Tranylcypromine.]
[N06AA16, dothiepin, Tranylcypromine may increase the serotonergic activities of Dosulepin.]
[R07AB01, doxapram, Tranylcypromine may increase the hypertensive activities of Doxapram.]
[N06AA12, doxepin, Tranylcypromine may increase the serotonergic activities of Doxepin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.]
[N06AB06, sertraline, The risk or severity of serotonin syndrome can be increased when Sertraline is combined with Tranylcypromine.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Tranylcypromine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.]
[A08AA10, sibutramine, Tranylcypromine may increase the serotonergic activities of Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Tranylcypromine.]
[C09AA11, spirapril, Tranylcypromine may increase the hypotensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sultopride.]
[N02CC01, sumatriptan, The metabolism of Sumatriptan can be decreased when combined with Tranylcypromine.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Tranylcypromine.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be decreased when combined with Tranylcypromine.]
[G04CA03, terazosin, Tranylcypromine may increase the hypotensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Tranylcypromine.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Tranylcypromine.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiopropazate.]
[G04BD01, emepronium, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Tianeptine is combined with Tranylcypromine.]
[C09AA02, enalapril, Tranylcypromine may increase the hypotensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Atomoxetine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Tranylcypromine.]
[C03CA04, torsemide, Tranylcypromine may increase the hypotensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tramazoline.]
[C09AA10, trandolapril, Tranylcypromine may increase the hypotensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triclofos.]
[A03AB08, tridihexethyl, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Triflusal.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Tranylcypromine.]
[N04AA12, tropatepine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Troxerutin.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Tranylcypromine.]
[C02CA06, urapidil, Tranylcypromine may increase the hypotensive activities of Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Veralipride.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Ephedrine.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Tranylcypromine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Venlafaxine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Xamoterol.]
[S01GA03, xylometazoline, Tranylcypromine may increase the hypertensive activities of Xylometazoline.]
[C08CA12, mepirodipine, Tranylcypromine may increase the orthostatic hypotensive activities of Barnidipine.]
[S01EA01, epinephrine, Tranylcypromine may increase the hypertensive activities of Epinephrine.]
[C09AA15, zofenopril, Tranylcypromine may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Tranylcypromine is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Tranylcypromine.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zotepine.]
[B01AD03, anistreplase, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Anistreplase.]
[C02AC02, guanfacine, Tranylcypromine may increase the hypotensive activities of Guanfacine.]
[B01AC11, iloprost, Tranylcypromine may increase the orthostatic hypotensive activities of Iloprost.]
[C01BG01, moricizine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Moricizine.]
[G02AB03, ergonovine, Tranylcypromine may increase the hypertensive activities of Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Tranylcypromine.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be decreased when combined with Tranylcypromine.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Estazolam.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Tranylcypromine.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Tranylcypromine.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Tranylcypromine.]
[C01CA15, gepefrine, Tranylcypromine may increase the hypertensive activities of Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Tranylcypromine.]
[V03AF05, amifostine, Tranylcypromine may increase the orthostatic hypotensive activities of Amifostine.]
[N04AA05, profenamine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Tranylcypromine.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethotoin.]
[M01AC06, meloxicam, The metabolism of Meloxicam can be decreased when combined with Tranylcypromine.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tranylcypromine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Tranylcypromine.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Tranylcypromine.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Tranylcypromine.]
[R06AX12, terfenadine, The metabolism of Terfenadine can be decreased when combined with Tranylcypromine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bupropion.]
[N06AB08, fluvoxamine, Tranylcypromine may increase the serotonergic activities of Fluvoxamine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Tranylcypromine.]
[B05AA05, dextran, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Dextran.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Tranylcypromine.]
[C08CA02, felodipine, Tranylcypromine may increase the hypotensive activities of Felodipine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Tranylcypromine.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Fenoterol.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Tranylcypromine.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Salbutamol.]
[B01AD05, plasmin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Fibrinolysin.]
[L01BB06, clofarabine, Tranylcypromine may increase the orthostatic hypotensive activities of Clofarabine.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Tranylcypromine.]
[G04BD02, flavoxate, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Tranylcypromine.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Floctafenine.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Tranylcypromine.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Tranylcypromine.]
[N06AA14, melitracen, Tranylcypromine may increase the serotonergic activities of Melitracen.]
[V03AZ01, ethanol, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Tranylcypromine.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Fluoxetine.]
[N05AF01, flupenthixol, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Fluphenazine.]
[N05CD01, flurazepam, The metabolism of Flurazepam can be decreased when combined with Tranylcypromine.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Tranylcypromine.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluspirilene.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Tranylcypromine.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Tranylcypromine.]
[C03CA01, furosemide, Tranylcypromine may increase the hypotensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Tranylcypromine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Tranylcypromine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gallamine.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Tranylcypromine.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bifemelane.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Tranylcypromine.]
[A10BJ02, liraglutide, Tranylcypromine may increase the hypoglycemic activities of Liraglutide.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Tranylcypromine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Tranylcypromine.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Tranylcypromine.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Tranylcypromine.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Tranylcypromine.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Tranylcypromine.]
[N05CM18, dexmedetomidine, Tranylcypromine may increase the orthostatic hypotensive activities of Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Glutethimide.]
[C05AE01, nitroglycerin, Tranylcypromine may increase the hypotensive activities of Nitroglycerin.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Tranylcypromine.]
[C07AB09, esmolol, The metabolism of Esmolol can be decreased when combined with Tranylcypromine.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Tranylcypromine.]
[C09AA09, fosinopril, Tranylcypromine may increase the hypotensive activities of Fosinopril.]
[S01EX01, guanethidine, Tranylcypromine may increase the hypotensive activities of Guanethidine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tranylcypromine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Tranylcypromine.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be decreased when combined with Tranylcypromine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Tranylcypromine is combined with Insulin aspart.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Allobarbital.]
[C09CA01, losartan, Tranylcypromine may increase the hypotensive activities of Losartan.]
[S01XA14, heparin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Heparin.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Tranylcypromine.]
[L01XX03, altretamine, Altretamine may increase the orthostatic hypotensive activities of Tranylcypromine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Tranylcypromine.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Tranylcypromine.]
[C08CA10, nilvadipine, Tranylcypromine may increase the hypotensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Nimesulide.]
[C09AA04, perindopril, Tranylcypromine may increase the hypotensive activities of Perindopril.]
[C02DB02, hydralazine, Tranylcypromine may increase the hypotensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Tranylcypromine may increase the hypotensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, Tranylcypromine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Tranylcypromine may increase the hypotensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Tranylcypromine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.]
[C02AC06, rilmenidine, Tranylcypromine may increase the hypotensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Tranylcypromine.]
[B05CB02, sodium citrate, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Tranylcypromine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Tranylcypromine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Tranylcypromine.]
[N06AA02, imipramine, Tranylcypromine may increase the serotonergic activities of Imipramine.]
[L01CD01, paclitaxel, Tranylcypromine may increase the orthostatic hypotensive activities of Paclitaxel.]
[M03BX02, tizanidine, Tranylcypromine may increase the orthostatic hypotensive activities of Tizanidine.]
[C03BA11, indapamide, Tranylcypromine may increase the hypotensive activities of Indapamide.]
[S01BC01, indomethacin, The metabolism of Indomethacin can be decreased when combined with Tranylcypromine.]
[C02CA02, indoramin, Tranylcypromine may increase the hypotensive activities of Indoramin.]
[N06AX17, milnacipran, Tranylcypromine may increase the serotonergic activities of Milnacipran.]
[A03AA30, piperidolate, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Articaine.]
[A10BH01, sitagliptin, Tranylcypromine may increase the hypoglycemic activities of Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Tranylcypromine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ramelteon.]
[R06AE01, buclizine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, Tranylcypromine may increase the hypoglycemic activities of Vildagliptin.]
[L01XX35, anagrelide, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Anagrelide.]
[C07AA01, alprenolol, The metabolism of Alprenolol can be decreased when combined with Tranylcypromine.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Tranylcypromine.]
[N06AA13, iprindole, Tranylcypromine may increase the serotonergic activities of Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isocarboxazid.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Tranylcypromine.]
[C09AA16, imidapril, Tranylcypromine may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Tranylcypromine.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Tranylcypromine.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Isoniazid.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Isoprenaline.]
[A10BJ01, exenatide, Tranylcypromine may increase the hypoglycemic activities of Exenatide.]
[C01DA14, isosorbide mononitrate, Tranylcypromine may increase the orthostatic hypotensive activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, Tranylcypromine may increase the orthostatic hypotensive activities of Isosorbide dinitrate.]
[C04AA01, isoxsuprine, Tranylcypromine may increase the orthostatic hypotensive activities of Isoxsuprine.]
[B01AE06, bivalirudin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Bivalirudin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Tranylcypromine.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketamine.]
[C02KD01, ketanserin, Tranylcypromine may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Prasugrel.]
[N05AH03, olanzapine, The metabolism of Olanzapine can be decreased when combined with Tranylcypromine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Ketoprofen.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Arbutamine.]
[N04BC09, rotigotine, Tranylcypromine may increase the sedative activities of Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Tranylcypromine.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Amantadine.]
[C02AA05, deserpidine, Tranylcypromine may increase the hypotensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lacosamide.]
[C03CC01, ethacrynic acid, Tranylcypromine may increase the orthostatic hypotensive activities of Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levodopa.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be decreased when combined with Tranylcypromine.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Tranylcypromine.]
[C03DB01, amiloride, Tranylcypromine may increase the orthostatic hypotensive activities of Amiloride.]
[N02CA07, lisuride, The metabolism of Lisuride can be decreased when combined with Tranylcypromine.]
[N06AA07, lofepramine, Tranylcypromine may increase the serotonergic activities of Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Tranylcypromine.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Tranylcypromine.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Loxapine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Tranylcypromine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Tranylcypromine can be increased when used in combination with Magnesium sulfate.]
[V04CX04, mannitol, Tranylcypromine may increase the orthostatic hypotensive activities of Mannitol.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be decreased when combined with Tranylcypromine.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Tranylcypromine.]
[C02BB01, mecamylamine, Tranylcypromine may increase the hypotensive activities of Mecamylamine.]
[R06AE05, meclizine, The metabolism of Meclizine can be decreased when combined with Tranylcypromine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Medazepam.]
[B01AB06, nadroparin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Dalteparin.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Melatonin.]
[N02AB02, meperidine, The risk or severity of serotonin syndrome and opioid toxicity can be increased when Tranylcypromine is combined with Meperidine.]
[C01CA11, mephentermine, Tranylcypromine may increase the hypertensive activities of Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Tranylcypromine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Tranylcypromine.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Meptazinol is combined with Tranylcypromine.]
[N05AC03, mesoridazine, The metabolism of Mesoridazine can be decreased when combined with Tranylcypromine.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be decreased when combined with Tranylcypromine.]
[C01CA09, metaraminol, Tranylcypromine may increase the hypertensive activities of Metaraminol.]
[A10BA02, metformin, Tranylcypromine may increase the hypoglycemic activities of Metformin.]
[A04AA04, dolasetron, The metabolism of Dolasetron can be decreased when combined with Tranylcypromine.]
[N07BC02, methadone, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Methadone.]
[N06BA03, methamphetamine, Tranylcypromine may increase the hypertensive activities of Metamfetamine.]
[A03AB07, methantheline, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Tranylcypromine.]
[S01EC05, methazolamide, Tranylcypromine may increase the orthostatic hypotensive activities of Methazolamide.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metergoline.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Tranylcypromine.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Tranylcypromine.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, Tranylcypromine may increase the hypertensive activities of Methoxamine.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Tranylcypromine.]
[C03AA08, methyclothiazide, Tranylcypromine may increase the orthostatic hypotensive activities of Methyclothiazide.]
[C02AB01, methyldopa, Tranylcypromine may decrease the hypotensive activities of Methyldopa.]
[V04CG05, methylene blue, Tranylcypromine may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Tranylcypromine.]
[N06BA04, methylphenidate, Tranylcypromine may increase the hypertensive activities of Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Tranylcypromine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Tranylcypromine.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metoclopramide.]
[C03BA08, metolazone, Tranylcypromine may increase the hypotensive activities of Metolazone.]
[C07AB02, metoprolol, The metabolism of Metoprolol can be decreased when combined with Tranylcypromine.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be decreased when combined with Tranylcypromine.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Tranylcypromine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Tranylcypromine.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Tranylcypromine.]
[B01AB07, parnaparin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Tranylcypromine.]
[C01CA17, midodrine, Tranylcypromine may increase the hypertensive activities of Midodrine.]
[G03XB01, mifepristone, Tranylcypromine may increase the hypoglycemic activities of Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tinzaparin.]
[C09CA03, valsartan, Tranylcypromine may increase the hypotensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.]
[D11AX01, minoxidil, Tranylcypromine may increase the hypotensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, Tranylcypromine may increase the hypertensive activities of Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Molindone.]
[L03AC01, aldesleukin, Tranylcypromine may increase the orthostatic hypotensive activities of Aldesleukin.]
[C01BD01, amiodarone, Tranylcypromine may increase the orthostatic hypotensive activities of Amiodarone.]
[N06AA09, amitriptyline, Tranylcypromine may increase the serotonergic activities of Amitriptyline.]
[N02AA01, morphine, Tranylcypromine may increase the analgesic activities of Morphine.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Tranylcypromine.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Tranylcypromine.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vecuronium.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Tranylcypromine.]
[R03BB01, ipratropium bromide, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Tranylcypromine may increase the serotonergic activities of Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Tranylcypromine.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Tranylcypromine.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Tranylcypromine.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Tranylcypromine.]
[S01GA01, naphazoline, The risk or severity of CNS depression can be increased when Naphazoline is combined with Tranylcypromine.]
[N06BA01, amphetamine, Tranylcypromine may increase the hypertensive activities of Amphetamine.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Tranylcypromine.]
[A10BG01, troglitazone, The metabolism of Troglitazone can be decreased when combined with Tranylcypromine.]
[N06AX21, duloxetine, The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Duloxetine.]
[N04BX01, tolcapone, Tranylcypromine may increase the orthostatic hypotensive activities of Tolcapone.]
[L02BG04, letrozole, The metabolism of Letrozole can be decreased when combined with Tranylcypromine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Tranylcypromine.]
[A10BX02, repaglinide, Tranylcypromine may increase the hypoglycemic activities of Repaglinide.]
[C01CX08, levosimendan, Tranylcypromine may increase the orthostatic hypotensive activities of Levosimendan.]
[B01AC17, tirofiban, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tirofiban.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Tranylcypromine.]
[J02AA01, amphotericin B, Tranylcypromine may increase the orthostatic hypotensive activities of Amphotericin B.]
[N06AX23, desvenlafaxine, Tranylcypromine may increase the serotonergic activities of Desvenlafaxine.]
[C09CA07, telmisartan, Tranylcypromine may increase the hypotensive activities of Telmisartan.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nialamide.]
[C08CA04, nicardipine, Tranylcypromine may increase the hypotensive activities of Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Tranylcypromine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Tranylcypromine.]
[N07BA01, nicotine, The metabolism of Nicotine can be decreased when combined with Tranylcypromine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Tranylcypromine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Niflumic acid.]
[V03AB22, amyl nitrite, Tranylcypromine may increase the orthostatic hypotensive activities of Amyl Nitrite.]
[C08CA06, nimodipine, Tranylcypromine may increase the hypotensive activities of Nimodipine.]
[C08CA07, nisoldipine, Tranylcypromine may increase the hypotensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nitrazepam.]
[C08CA08, nitrendipine, Tranylcypromine may increase the hypotensive activities of Nitrendipine.]
[R07AX01, nitric oxide, Tranylcypromine may increase the orthostatic hypotensive activities of Nitric Oxide.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zaleplon.]
[N04BC05, pramipexole, Tranylcypromine may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Tranylcypromine may increase the hypotensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tranylcypromine.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nomifensine.]
[C01CA03, norepinephrine, Tranylcypromine may increase the hypertensive activities of Norepinephrine.]
[C02KX01, bosentan, Tranylcypromine may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, Tranylcypromine may increase the serotonergic activities of Nortriptyline.]
[B01AC16, eptifibatide, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Eptifibatide.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Reviparin.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Tranylcypromine.]
[N06AA05, opipramol, Tranylcypromine may increase the serotonergic activities of Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Opium is combined with Tranylcypromine.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Orciprenaline.]
[B01AD07, reteplase, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Ancrod.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Tranylcypromine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxazepam.]
[C07AA02, oxprenolol, The metabolism of Oxprenolol can be decreased when combined with Tranylcypromine.]
[N02AA05, oxycodone, Tranylcypromine may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The serum concentration of Oxymetazoline can be increased when it is combined with Tranylcypromine.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Tranylcypromine.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Danaparoid.]
[N02AX06, tapentadol, The risk or severity of adverse effects can be increased when Tapentadol is combined with Tranylcypromine.]
[M03AC01, pancuronium, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G04BE02, papaverine, Tranylcypromine may increase the orthostatic hypotensive activities of Papaverine.]
[N05CC05, paraldehyde, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pargyline.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Tranylcypromine.]
[C07AA23, penbutolol, The metabolism of Penbutolol can be decreased when combined with Tranylcypromine.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Tranylcypromine.]
[C04AD03, pentoxifylline, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Perazine.]
[N04BC02, pergolide, Tranylcypromine may increase the hypertensive activities of Pergolide.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Tranylcypromine.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Tranylcypromine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Tranylcypromine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Phenazocine is combined with Tranylcypromine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenelzine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Tranylcypromine.]
[B01AA02, phenindione, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Tranylcypromine.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Phenoperidine is combined with Tranylcypromine.]
[C04AX02, phenoxybenzamine, Tranylcypromine may increase the hypotensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Tranylcypromine.]
[A08AA01, phentermine, Tranylcypromine may increase the hypertensive activities of Phentermine.]
[V03AB36, phentolamine, Tranylcypromine may increase the hypotensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The metabolism of Phenylbutazone can be decreased when combined with Tranylcypromine.]
[S01GA05, phenylephrine, Tranylcypromine may increase the hypertensive activities of Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Tranylcypromine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Tranylcypromine.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Tranylcypromine.]
[C08CX01, mibefradil, Tranylcypromine may increase the hypotensive activities of Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Tranylcypromine.]
[C07AA03, pindolol, The metabolism of Pindolol can be decreased when combined with Tranylcypromine.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Tranylcypromine.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Tranylcypromine.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Tranylcypromine.]
[C09CA02, eprosartan, Tranylcypromine may increase the hypotensive activities of Eprosartan.]
[A02BX03, pirenzepine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Piritramide is combined with Tranylcypromine.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Tranylcypromine.]
[N02CX01, pizotyline, Tranylcypromine may increase the anticholinergic activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Delavirdine can be decreased when combined with Tranylcypromine.]
[C09CA04, irbesartan, Tranylcypromine may increase the hypotensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Proxibarbal.]
[B01AC13, abciximab, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Alteplase.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Tranylcypromine.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alosetron.]
[C03AA05, polythiazide, Tranylcypromine may increase the hypotensive activities of Polythiazide.]
[J05AE03, ritonavir, The metabolism of Ritonavir can be decreased when combined with Tranylcypromine.]
[A10BH03, saxagliptin, Tranylcypromine may increase the hypoglycemic activities of Saxagliptin.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Tranylcypromine is combined with Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Tranylcypromine.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Tranylcypromine.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Tranylcypromine.]
[C02CA01, prazosin, Tranylcypromine may increase the hypotensive activities of Prazosin.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Tranylcypromine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Tranylcypromine.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Tranylcypromine.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Tranylcypromine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Tranylcypromine.]
[N05AB04, prochlorperazine, The metabolism of Prochlorperazine can be decreased when combined with Tranylcypromine.]
[N04AA04, procyclidine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Tranylcypromine.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Tranylcypromine.]
[R06AD02, promethazine, The metabolism of Promethazine can be decreased when combined with Tranylcypromine.]
[C01BC03, propafenone, The metabolism of Propafenone can be decreased when combined with Tranylcypromine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propanidid.]
[A03AB05, propantheline, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Periciazine.]
[N05CM06, propiomazine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, Tranylcypromine may increase the orthostatic hypotensive activities of Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tranylcypromine.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Tranylcypromine.]
[N02CC04, rizatriptan, The metabolism of Rizatriptan can be decreased when combined with Tranylcypromine.]
[B01AC09, epoprostenol, Tranylcypromine may increase the hypotensive activities of Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Tranylcypromine.]
[N06AA11, protriptyline, Tranylcypromine may increase the serotonergic activities of Protriptyline.]
[R01BA02, pseudoephedrine, Tranylcypromine may increase the hypertensive activities of Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Tranylcypromine.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Tranylcypromine is combined with Dalfampridine.]
[A03AB15, diphemanil, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Tranylcypromine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mepyramine.]
[C01BA01, quinidine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Quinidine.]
[P01BC01, quinine, The metabolism of Quinine can be decreased when combined with Tranylcypromine.]
[C02AA01, rescinnamine, Tranylcypromine may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Reserpine.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxitriptan.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Tranylcypromine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Tranylcypromine.]
[S01FA02, scopolamine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Tranylcypromine.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Tranylcypromine.]
[L01FA03, obinutuzumab, Tranylcypromine may increase the orthostatic hypotensive activities of Obinutuzumab.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Tranylcypromine.]
[C03DA01, spironolactone, Tranylcypromine may increase the orthostatic hypotensive activities of Spironolactone.]
[N02AX02, tramadol, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[N06AA06, trimipramine, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N02CC03, zolmitriptan, Triptans - monoamine oxidase (MAO) inhibitors]
[N06AB04, citalopram, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AA04, clomipramine, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N06AX06, nefazodone, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AB10, escitalopram, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AA01, desipramine, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N06BA02, dextroamphetamine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[R05DA09, dextromethorphan, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[N06AB05, paroxetine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[A08AA03, diethylpropion, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06BA11, dexmethylphenidate, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AA12, doxepin, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N06AB06, sertraline, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N02CC01, sumatriptan, Triptans - monoamine oxidase (MAO) inhibitors]
[N06BA09, atomoxetine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AX16, venlafaxine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AB08, fluvoxamine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N02AB03, fentanyl, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[N06AB03, fluoxetine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AA02, imipramine, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N06AX17, milnacipran, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N02AB02, meperidine, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[N07BC02, methadone, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[N06BA03, methamphetamine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06BA04, methylphenidate, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06BA12, lisdexamfetamine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AA09, amitriptyline, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N06AA17, amoxapine, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N06BA01, amphetamine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AX21, duloxetine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AX23, desvenlafaxine, Selective serotonin reuptake inhibitors (SSRIs) -  monoamine oxidase (MAO) inhibitors]
[N06AA10, nortriptyline, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[N02AX06, tapentadol, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[A08AA01, phentermine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[L01XB01, procarbazine, Tranylcypromine - procarbazine]
[N02CC04, rizatriptan, Triptans - monoamine oxidase (MAO) inhibitors]
[N06AA11, protriptyline, Tricyclic antidepressants (TCAs) - monoamine oxidase (MAO) inhibitors]
[R01BA02, pseudoephedrine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
